Your browser doesn't support javascript.
loading
A drug-free nanozyme for mitigating oxidative stress and inflammatory bowel disease.
Zeng, Feng; Shi, Yahong; Wu, Chunni; Liang, Jianming; Zhong, Qixin; Briley, Karen; Xu, Bin; Huang, Yongzhuo; Long, Manmei; Wang, Cong; Chen, Jian; Tang, Yonghua; Li, Xinying; Jiang, Mengda; Wang, Luting; Xu, Qin; Yang, Liu; Chen, Peng; Duan, Shengzhong; Xie, Jingyuan; Li, Cong; Wu, Yingwei.
Afiliação
  • Zeng F; Artemisinin Research Center, Institute of Science and Technology, The First Affiliated Hospital, The First Clinical Medical School, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510450, China.
  • Shi Y; Department of Radiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
  • Wu C; Artemisinin Research Center, Institute of Science and Technology, The First Affiliated Hospital, The First Clinical Medical School, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510450, China.
  • Liang J; Artemisinin Research Center, Institute of Science and Technology, The First Affiliated Hospital, The First Clinical Medical School, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510450, China.
  • Zhong Q; Department of Cardiovascular, Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, 518034, China.
  • Briley K; Invicro, A Konica Minolta Company, Boston, MA, 02210, USA.
  • Xu B; Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200020, China.
  • Huang Y; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Long M; Zhongshan Institute for Drug Discovery and Development, Chinese Academy of Sciences, Zhongshan, 528437, China.
  • Wang C; School of Advanced Study, Institute of Natural Medicine and Health Product, Taizhou University, Taizhou, 318000, China.
  • Chen J; Department of Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
  • Tang Y; Key Laboratory of Smart Drug Deliver, Ministry of Education, School of Pharmacy, Fudan University, Shanghai, 201213, China.
  • Li X; China Academy for Engineering and Technology, Fudan University, Shanghai, 200433, China.
  • Jiang M; Key Laboratory of Smart Drug Deliver, Ministry of Education, School of Pharmacy, Fudan University, Shanghai, 201213, China.
  • Wang L; Radiology Department, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200020, China.
  • Xu Q; Department of Radiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
  • Yang L; Department of Radiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
  • Chen P; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Duan S; Artemisinin Research Center, Institute of Science and Technology, The First Affiliated Hospital, The First Clinical Medical School, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510450, China.
  • Xie J; Department of Molecular Diagnostics, The Core Laboratory in Medical Center of Clinical Research, Department of Endocrinology, State Key Laboratory of Medical Genomics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
  • Li C; Artemisinin Research Center, Institute of Science and Technology, The First Affiliated Hospital, The First Clinical Medical School, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510450, China.
  • Wu Y; Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200125, China.
J Nanobiotechnology ; 20(1): 107, 2022 Mar 04.
Article em En | MEDLINE | ID: mdl-35246140
ABSTRACT
Inflammatory bowel disease (IBD) is an incurable disease of the gastrointestinal tract with a lack of effective therapeutic strategies. The proinflammatory microenvironment plays a significant role in both amplifying and sustaining inflammation during IBD progression. Herein, biocompatible drug-free ceria nanoparticles (CeNP-PEG) with regenerable scavenging activities against multiple reactive oxygen species (ROS) were developed. CeNP-PEG exerted therapeutic effect in dextran sulfate sodium (DSS)-induced colitis murine model, evidenced by corrected the disease activity index, restrained colon length shortening, improved intestinal permeability and restored the colonic epithelium disruption. CeNP-PEG ameliorated the proinflammatory microenvironment by persistently scavenging ROS, down-regulating the levels of multiple proinflammatory cytokines, restraining the proinflammatory profile of macrophages and Th1/Th17 response. The underlying mechanism may involve restraining the co-activation of NF-κB and JAK2/STAT3 pathways. In summary, this work demonstrates an effective strategy for IBD treatment by ameliorating the self-perpetuating proinflammatory microenvironment, which offers a new avenue in the treatment of inflammation-related diseases.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Colite Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Colite Idioma: En Ano de publicação: 2022 Tipo de documento: Article